Timing of rejection events preceded by Covid-19 mRNA vaccination in recipients of solid organ transplants

IF 4.5 3区医学 Q2 IMMUNOLOGY Vaccine Pub Date : 2025-01-25 DOI:10.1016/j.vaccine.2024.126617

Quentin Perrier , Johan Noble , Agnès Bonadona , Caroline Augier , Thomas Jouve , Aude Boignard , Loïc Falque , Salomé Gallet , Pierrick Bedouch , Lionel Rostaing , Olivier Epaulard , on behalf of INTEGRAL Study Group

{"title":"Timing of rejection events preceded by Covid-19 mRNA vaccination in recipients of solid organ transplants","authors":"Quentin Perrier , Johan Noble , Agnès Bonadona , Caroline Augier , Thomas Jouve , Aude Boignard , Loïc Falque , Salomé Gallet , Pierrick Bedouch , Lionel Rostaing , Olivier Epaulard , on behalf of INTEGRAL Study Group","doi":"10.1016/j.vaccine.2024.126617","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>SARS-CoV-2 mRNA vaccine reactogenicity has raised concerns regarding the risk of rejection in solid organ transplant recipients. We explored whether SOT recipients diagnosed with acute rejection had previously received a vaccine injection within a timeframe consistent with a causal link.</div></div><div><h3>Methods</h3><div>We identified all SOT recipients with a diagnosis of acute rejection from 2020 to 2022 and who had previously received a SARS-CoV-2 vaccination, and analysed whether the delay between vaccination and rejection was constant.</div></div><div><h3>Results</h3><div>In the 45 identified patients, median delay between the last SARS-CoV-2 vaccination and the rejection was 102 days [IQR 48–178]; the continuous distribution of this delay, with no identifiable time pattern, is not in favor of a role of vaccination in rejection.</div></div><div><h3>Conclusion</h3><div>SARS-CoV-2 mRNA vaccination is unlikely to trigger rejection in SOT recipients.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"45 ","pages":"Article 126617"},"PeriodicalIF":4.5000,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0264410X24012994","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives

SARS-CoV-2 mRNA vaccine reactogenicity has raised concerns regarding the risk of rejection in solid organ transplant recipients. We explored whether SOT recipients diagnosed with acute rejection had previously received a vaccine injection within a timeframe consistent with a causal link.

Methods

We identified all SOT recipients with a diagnosis of acute rejection from 2020 to 2022 and who had previously received a SARS-CoV-2 vaccination, and analysed whether the delay between vaccination and rejection was constant.

Results

In the 45 identified patients, median delay between the last SARS-CoV-2 vaccination and the rejection was 102 days [IQR 48–178]; the continuous distribution of this delay, with no identifiable time pattern, is not in favor of a role of vaccination in rejection.

Conclusion

SARS-CoV-2 mRNA vaccination is unlikely to trigger rejection in SOT recipients.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

实体器官移植受者接种Covid-19 mRNA后排斥事件发生的时间

目的：SARS-CoV-2 mRNA疫苗的反应原性引起了对实体器官移植受者排斥风险的关注。我们探讨了被诊断为急性排斥反应的SOT受者是否曾在与因果关系一致的时间框架内接受过疫苗注射。方法：选取2020年至2022年期间所有诊断为急性排斥反应并曾接种过SARS-CoV-2疫苗的SOT接受者，分析疫苗接种与排斥反应之间的延迟是否恒定。结果：在45例确诊患者中，从最后一次接种SARS-CoV-2到排斥反应的中位延迟时间为102 d [IQR 48-178]；这种延迟的连续分布，没有可识别的时间模式，不利于疫苗接种在排斥反应中的作用。结论：接种SARS-CoV-2 mRNA不太可能引发SOT受者的排斥反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Vaccine 医学-免疫学

CiteScore

8.70

自引率

5.50%

发文量

992

审稿时长

131 days

期刊介绍： Vaccine is unique in publishing the highest quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas are welcomed. The submission categories as given in the Guide for Authors indicate where we receive the most papers. Papers outside these major areas are also welcome and authors are encouraged to contact us with specific questions.